Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 2, 2008

Roche to Distribute DxS’ K-RAS and EGFR Cancer Mutation Tests

  • Roche signed on to be a distributor of DxS’ TheraScreen K-RAS and EGFR 29 Mutation Tests. Roche will have exclusive, worldwide distribution rights for the K-RAS Test. For the EGFR test, Roche will be granted exclusive distribution rights for all global markets except the U.S., Canada, Mexico, and Hong Kong.

    The TheraScreen K-RAS Mutation Test was, according to the companies, the first clinically validated, CE-Mark certified companion diagnostic for tumor-specific mutations in patients with colorectal cancer. The test detects seven mutations in codons 12 and 13 of the K-RAS oncogene, which are frequently found in many cancer types.

    The TheraScreen EGFR 29 Test, which also has CE-Mark certification, is designed to enable detection of 29 of the most common somatic mutations in the EGFR gene and reportedly detects mutations with greater sensitivity than sequencing. Recent studies in non-small-cell lung cancer have shown that some patients carry somatic mutations in the EGFR gene.

    These mutations may correlate with responsiveness to the EGFR tyrosine kinase inhibitors, with some mutations having a sensitizing effect and others being linked to resistance.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »